ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $590.25 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2025-03-28
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $44.25.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $590.25, a 1181.76% increase from fiscal 2023.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $46.05, a 73.69% decline from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $175.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $590.25 10-K · filed 2025-03-28 | ||||
| 2024-09-30 | $39.35 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $39.35 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | $44.25 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $46.05 10-K · filed 2025-03-28 | $3.07 10-K · filed 2024-03-26 | |||
| 2023-09-30 | $5.79 10-Q · filed 2023-11-13 | ||||
| 2022-12-31 | $175.00 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | $175.00 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $175.00 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |